Cellectis

CLLS

Market cap $408M

(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)

Shares of Cellectis S.A. (NASDAQ: CLLS) tanked on Tuesday after Allogene Therapeutics Inc. (NASDAQ: ALLO) cited a favorable arbitration outcome for partner Servier in its dispute with Cellectis related to the CAR-T therapy cemacabtagene ansegedleucel (cema-cel).

Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights 1H 2026 Interim Futility Analysis from the Pivotal Phase 2 ALPHA3 Trial with Cema-Cel in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Remains on Track SOUTH SAN FRANCISCO, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today noted the favorable outcome for Servier in its arbitration with Cellectis (Euronext Growth: ALCLS –  NASDAQ: CLLS) as it relates to cemacabtagene ansegedleucel (cema-cel).

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces that the Arbitral Tribunal has issued its decision in the arbitration proceedings against Les Laboratoires Servier and Institut de Recherches Internationales Servier IRIS SARL (“Servier”), relating to the License, Development and Commercialization Agreement entered into between Servier and Cellectis on March 6, 2019, as amended (the “License Agreement”).

CELLS develops off-the-shelf TALEN-edited CAR-T therapies. Its main in-house asset is lasme-cel for r/r B-ALL and eti-cel for r/r B-cell NHL. Early data show that lasme-cel reached impressive ORRs in Phase 1, and CLLS should give us a pivotal Phase 2 readout expected in 2026. CLLS also has partnerships with big pharma companies like Allogene, Servier, Iovance, and AstraZeneca that should provide added optionality.

NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced the presentation of encouraging updated data of patients treated in the Phase 1 NATHALI-01 clinical trial with eti-cel, at the 67th Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL.

(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today publishes an article in Nature Communications establishing circular single-stranded DNA (CssDNA) as a highly efficient non-viral DNA donor template, for gene insertion in hematopoietic stem and progenitor cells (HSPCs).

Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) Median OS of 14.8 months in patients who achieved MRD-negative CR/CRi First interim analysis for the BALLI-01 trial expected in Q4 2026 Eti-cel in r/r NHL  (NATHALI-01) ORR of 86% and 57% CR rate (n=7) Development update to be presented at the ASH 2025 annual meeting Full Phase 1 dataset expected to be shared in 2026 Servier arbitration: arbitral decision expected to be rendered on or before December 15, 2025 Cash, cash equivalents and fixed-term deposits of $225 million as of September 30, 2025 1 provides runway into H2 2027 NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided financial results for the third quarter 2025 ending September 30, 2025 and business updates. “We are proud of the promising data from our core clinical product candidates.

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the acceptance of two abstracts for poster presentation at the American Society of Hematology (ASH) 2025 annual meeting taking place from December 6 to 9, 2025, in Orlando, FL.